Safety and efficacy of fosamprenavir in human immunodeficiency virus-infected pregnant women.
Martorell
Claudia
C
Theroux
Eileen
E
Bermudez
Arlene
A
Garb
Jane
J
Kronschnabel
Debra
D
Oie
Katrina
K
D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects / Q000379:methods; D002219:Carbamates / Q000009:adverse effects* / Q000627:therapeutic use*; D005260:Female; D005663:Furans; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D010755:Organophosphates / Q000009:adverse effects* / Q000627:therapeutic use*; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy*; D012189:Retrospective Studies; D013449:Sulfonamides / Q000009:adverse effects* / Q000627:therapeutic use*; D016896:Treatment Outcome
D019380:Anti-HIV Agents; D002219:Carbamates; D005663:Furans; D010755:Organophosphates; D013449:Sulfonamides; C426859:fosamprenavir